Welcome to our dedicated page for Iradimed news (Ticker: IRMD), a resource for investors and traders seeking the latest updates and insights on Iradimed stock.
Iradimed Corporation (IRMD) provides essential medical technologies for MRI environments through its innovative devices. This news hub offers investors and healthcare professionals timely updates on product developments, financial performance, and operational milestones.
Access official press releases and verified news about IRMD's MRI-compatible infusion systems, patient monitoring solutions, and regulatory achievements. Stay informed about quarterly earnings, partnership announcements, and clinical validation studies that demonstrate the company's market leadership.
Key updates include FDA clearances, international expansion efforts, and technological enhancements to the company's non-magnetic device ecosystem. Content is organized chronologically showcase IRMD's progress in improving MRI safety standards while maintaining financial transparency.
Bookmark this page for direct access to primary source materials from Iradimed Corporation. Check regularly for updates on innovations addressing critical needs in diagnostic imaging and patient care during magnetic resonance procedures.
iRadimed (NASDAQ: IRMD) announced a special cash dividend of $0.50 per share, payable on December 30, 2025 to stockholders of record at the close of business on December 17, 2025.
The Board said the dividend follows strong financial results, including 17 consecutive quarters of record revenue and a cash and cash equivalents balance of $56.5 million at the end of Q3 2025. Management cited excess cash beyond needs for operations and the transition to a new manufacturing facility, and noted ongoing investments such as commercialization of the 3870 MRI IV pump.
The Board emphasized future dividends remain at its sole discretion and are subject to financial condition, cash flows, capital requirements and other factors.
IRADIMED CORPORATION (NASDAQ: IRMD) was named to TIME's America's Growth Leaders for 2026, placing 79th among the top 501 U.S. public companies selected by TIME and Statista. The ranking evaluated companies equally across Revenue Growth, Financial strength, and Stock Performance using a composite model.
The company highlighted its 17 consecutive quarters of record revenue and cited sustained financial health and strong stock performance as drivers of the recognition. Management credited the award to operational execution and innovation in MRI-compatible medical devices and thanked employees and shareholders for their support.
IRADIMED (NASDAQ: IRMD) reported record Q3 2025 revenue of $21.2M (+16% YoY) and record GAAP diluted EPS of $0.43 (non-GAAP diluted EPS $0.47, +9% YoY). The company raised full-year 2025 guidance to $82.5M–$83.5M revenue and GAAP EPS to $1.68–$1.72. Gross margin remained strong at 78%. The board declared a regular quarterly cash dividend of $0.17 per share payable Nov 25, 2025 (record date Nov 14, 2025). The new Orlando facility was completed (total cost ~$13.3M) and is fully operational; limited commercial shipments of the next‑gen 3870 pump are expected in Dec 2025 with full U.S. rollout in Q1 2026.
IRADIMED CORPORATION (NASDAQ: IRMD) will release its Q3 2025 financial results before the market opens on Monday, November 3, 2025. Management will host a conference call the same day at 11:00 a.m. Eastern Time to discuss results and answer questions.
Interested participants must register to receive a dial-in number and unique PIN via the provided registration link. A real-time webcast will be available at the company investor events page and a recording will be posted on the company website after the call.
IRADIMED CORPORATION (NASDAQ: IRMD), a leader in MRI-compatible patient monitoring and infusion systems, announced key changes to its Board of Directors. Anthony Vuoto, who served as director since 2016, has retired effective August 27, 2025. The company has appointed Joe Kiani, founder of Masimo Corporation, as his replacement effective September 2, 2025.
Kiani, a distinguished medical technology innovator with over 500 patents or patent applications, will serve on the Board's audit committee and as chairman of the compensation committee. He brings extensive experience from his roles as former Chairman and CEO of Masimo (1989-2024), current CEO of Willow Laboratories and Like Minded Labs, and board member of CDX Medical Technologies.
IRADIMED CORPORATION (NASDAQ: IRMD), a specialized manufacturer of MRI-compatible patient monitoring and infusion systems, has announced its participation in the upcoming Wells Fargo 2025 Healthcare Conference. The conference will take place from September 3-5, 2025, in Boston, Massachusetts.
The company's leadership, including President and CEO Roger Susi and CFO Jack Glenn, will conduct one-on-one meetings with investors on September 4, 2025. This invitation-only event brings together healthcare industry leaders and institutional investors to explore sector trends and opportunities.
Iradimed Corporation (NASDAQ:IRMD) reported record Q2 2025 financial results, with revenue reaching $20.4 million, a 14% increase year-over-year. The company achieved GAAP diluted EPS of $0.45 and non-GAAP diluted EPS of $0.49, marking increases of 18% and 17% respectively.
The company declared a quarterly dividend of $0.17 per share, payable on August 28, 2025. Iradimed raised its full-year 2025 guidance, now expecting revenue between $80.0-82.5 million and GAAP diluted EPS of $1.60-1.70.
Q2 highlights include a strong 78% gross profit margin, record backlog for pump and monitor products, and completion of a new facility in July 2025. For Q3 2025, the company projects revenue of $20.5-20.9 million with GAAP diluted EPS of $0.41-0.45.
Iradimed Corporation (NASDAQ: IRMD) has scheduled its second quarter 2025 financial results conference call for August 1, 2025. The company will release its financial results before the market opens, followed by a management-hosted conference call at 11:00 a.m. Eastern Time.
Participants can join the call by registering through the provided link, after which they will receive dial-in details and a unique pin. The call will also be available via live webcast on the company's investor relations website, with a recording accessible afterward.
Iradimed Corporation (NASDAQ: IRMD) has received FDA 510(k) clearance for its MRidium® 3870 IV Infusion Pump System, a next-generation MRI-compatible infusion pump. The device maintains Iradimed's unique position as the world's only provider of non-magnetic MRI infusion pumps since 2005. The new system features a non-magnetic ultrasonic pump motor, non-interfering RF emissions, and an enhanced touchscreen interface.
Key features include the ability to operate independently or as a four-channel system, and a modern drug library solution supporting multiple patient care areas. The company plans to begin deployment to select healthcare facilities in Q4 2025, with full commercial distribution ramping throughout 2026.
IRADIMED (NASDAQ: IRMD) reported strong Q1 2025 financial results with record revenue of $19.5 million, up 11% year-over-year. The company achieved GAAP diluted EPS of $0.37 and non-GAAP diluted EPS of $0.42, representing increases of 16% and 17% respectively. The Board declared a quarterly dividend of $0.17 per share, payable on May 30, 2025.
The company maintained its full-year 2025 guidance, expecting revenue between $78.0-82.0 million and GAAP diluted EPS of $1.55-1.65. For Q2 2025, IRADIMED projects revenue of $19.7-19.9 million. Domestic sales represented 82% of total revenue, and gross profit margin remained steady at 76.1%. The company's new manufacturing facility is on track for completion in July 2025, with approximately $3.0 million in remaining construction costs.
FAQ
What is the current stock price of Iradimed (IRMD)?
What is the market cap of Iradimed (IRMD)?
